Adial Pharmaceuticals Appoints David Rubenstein as Chief Scientist

Adial Pharmaceuticals appointed David Rubenstein as chief scientist to lead its research and scientific strategy. Rubenstein previously served as Dermavant Sciences’ chief scientific officer, leading tapinarof development through commercialization. He will oversee AT177 development for ulcerative colitis, with first-in-human trials expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 202610160700PRIMZONEFULLFEED9847117) on October 16, 2026, and is solely responsible for the information contained therein. (C)